{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:01:24Z","timestamp":1786118484246,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1097\/cad.0b013e3280113324","type":"journal-article","created":{"date-parts":[[2006,12,8]],"date-time":"2006-12-08T04:04:53Z","timestamp":1165550693000},"page":"233-235","source":"Crossref","is-referenced-by-count":5,"title":["Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer"],"prefix":"10.1097","volume":"18","author":[{"given":"Val\u00e9rie","family":"Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"D\u00f4mont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Bouscary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210227","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"R2-15-20210227","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00001622-200105000-00013","article-title":"An update on prostate cancer","volume":"13","author":"Rini","year":"2001","journal-title":"Curr Opin Oncol"},{"key":"R3-15-20210227","first-page":"258","article-title":"Management of hormone-sensitive metastatic prostate cancer","volume":"5","author":"Figg","year":"1997","journal-title":"Cancer Pract"},{"key":"R4-15-20210227","first-page":"428","article-title":"Chemotherapy in advanced prostate cancer","volume":"26","author":"Beedassy","year":"1999","journal-title":"Semin Oncol"},{"key":"R5-15-20210227","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1002\/1097-0142(20000615)88:12+<3015::AID-CNCR18>3.0.CO;2-M","article-title":"Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy","volume":"88","author":"Oh","year":"2000","journal-title":"Cancer"},{"key":"R6-15-20210227","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"R7-15-20210227","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"R8-15-20210227","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2004.05.074","article-title":"Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer","volume":"22","author":"Dahut","year":"2004","journal-title":"J Clin Oncol"},{"key":"R9-15-20210227","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJM199206253262605","article-title":"Risk of leukemia after chemotherapy and radiation treatment for breast cancer","volume":"326","author":"Curtis","year":"1992","journal-title":"N Engl J Med"},{"key":"R10-15-20210227","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1200\/JCO.2003.04.100","article-title":"Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Soci\u00e9t\u00e9 Francaise d'Oncologie P\u00e9diatrique","volume":"21","author":"Le Deley","year":"2003","journal-title":"J Clin Oncol"},{"key":"R11-15-20210227","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.2000.18.15.2836","article-title":"Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study","volume":"18","author":"Chaplain","year":"2000","journal-title":"J Clin Oncol"},{"key":"R12-15-20210227","first-page":"451","article-title":"Cancer Chemotherapy and Biotherapy. 4th ed","author":"Pommier","year":"2006"},{"key":"R13-15-20210227","first-page":"2978","article-title":"Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukaemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM)","volume":"90","author":"Harousseau","year":"1997","journal-title":"Blood"},{"issue":"6","key":"R14-15-20210227","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1212\/WNL.63.12_suppl_6.S28","article-title":"Mitoxantrone treatment of multiple sclerosis: safety considerations","volume":"63","author":"Cohen","year":"2004","journal-title":"Neurology"},{"key":"R15-15-20210227","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2004.06.016","article-title":"Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group","volume":"22","author":"Lenz","year":"2004","journal-title":"J Clin Oncol"},{"key":"R16-15-20210227","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"key":"R17-15-20210227","first-page":"1933","article-title":"Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease","volume":"92","author":"Andre","year":"1998","journal-title":"Blood"},{"key":"R18-15-20210227","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2000.18.5.947","article-title":"Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies","volume":"18","author":"Micallef","year":"2000","journal-title":"J Clin Oncol"},{"key":"R19-15-20210227","first-page":"246","article-title":"Value of autologous stem cell transplantation in first-line therapy of follicular lymphoma with high tumor burden: final results of the randomized GOELAMS 064 trial","volume":"102","author":"Deconinck","year":"2003","journal-title":"Blood"},{"key":"R20-15-20210227","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.1990.03450080092038","article-title":"Poor survival of treatment related acute nonlymphocytic leukemia","volume":"264","author":"Neugut","year":"1990","journal-title":"JAMA"},{"key":"R21-15-20210227","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1600-0609.1998.tb01069.x","article-title":"Outcome of secondary myeloid malignancy in Hodgkin's disease: the BNLI experience","volume":"61","author":"Harrison","year":"1998","journal-title":"Eur J Haematol"},{"key":"R22-15-20210227","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1200\/JCO.2003.07.160","article-title":"Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group","volume":"21","author":"Josting","year":"2003","journal-title":"J Clin Oncol"},{"key":"R23-15-20210227","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/beha.2000.0119","article-title":"Biology and therapy of secondary leukaemias","volume":"1","author":"Dann","year":"2001","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e3280113324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:10:01Z","timestamp":1786032601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200702000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e3280113324","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}